类风湿关节炎风险与应答的血清蛋白质组特征:RA拦截试验分析
基于APIPPRA试验118名参与者的440份血清样本,用SomaScan 7k检测平台分析进展为RA及阿巴西普治疗应答相关的血清蛋白特征。进展为RA与急性期反应物SAA1、SAA2升高及CTLA4降低相关,阿巴西普治疗则伴随CTLA4、CD86上调及CXCL13等7种蛋白下调。
要点
- RA发病前6至24个月已出现80种蛋白显著变化,以急性期蛋白为主。
- 进展为RA者SAA1、SAA2升高、CTLA4降低,提示风险特征。
- 阿巴西普治疗相关蛋白变化涉及CTLA4、CD86上调及CXCL13等下调。
核心结论
- 以急性期蛋白为主的蛋白特征定义进展为RA,阿巴西普相关变化提示治疗应答潜在机制。
研究设计与样本
- 从APIPPRA试验118名参与者中选取440份血清样本,含46例进展为RA者和72例未进展者。
- 样本用SomaScan 7k检测平台分析,比较进展与否及阿巴西普与安慰剂治疗分配。
主要发现
- RA发病前6至24个月至发病间有80种蛋白显著变化,其中68种下调、12种上调。
- 治疗结束时,进展为RA者较未进展者SAA1、SAA2升高、CTLA4降低。
- 无论RA结局如何,阿巴西普组较安慰剂组CTLA4、CD86上调,CXCL13、FCRL4、FCER2、CCL21、LTA|LTB、FDCSP、IL22RA2下调。
临床怎么用
- 血清蛋白特征有助于识别RA高危个体及理解阿巴西普应答机制,为RA预防提供新思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at-risk individuals. METHODS: A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA onset for 46 progressors of RA or to study end for 72 participants who did not develop RA. Samples were analyzed using the SomaScan 7k assay platform. Differential expression analysis was assessed by progression to RA (three pre-RA time intervals to RA, progressors of RA vs nonprogressors, baseline to RA), and by treatment allocation (abatacept vs placebo). Risk and response signatures were identified in the full 7k panel and two prespecified subpanels defined as Inflammatory Mediators and Adaptive Immune Cell panel. RESULTS: We observed significant changes in 80 proteins (68 down-regulated and 12 up-regulated) occurring between RA onset and 6 to 24 months before developing disease. Progression to RA was associated with increased levels of acute-phase reactants SAA1 and SAA2 and reductions in CTLA4, when compared to nonprogressors at the end of treatment. Two up-regulated proteins (CTLA4 and CD86) and seven down-regulated proteins (CXCL13, FCRL4, FCER2, CCL21, LTA|LTB, FDCSP, and IL22RA2) were observed in participants receiving abatacept compared to placebo regardless of RA outcome. CONCLUSION: Protein signatures dominated by acute-phase proteins define progression to RA, whereas changes associated with abatacept therapy highlight potential mechanisms of treatment response. Such signatures provide a better understanding of the immune landscape of the at-risk phase, opening up the possibility of new treatment modalities for RA prevention.
引用
- Jasenecova M, Coyle C, Mihalovits A, et al. Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial. Arthritis Rheumatol. 2026. PMID: 41657110. doi:10.1002/art.70082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。